Fig. 4: Validation of the Dragonfly Skin Infection Viral Test Panel.
From: Portable molecular diagnostic platform for rapid point-of-care detection of mpox and other diseases
a Evaluation of virucidal activity of eNAT® against vaccinia virus (VACV): Plaque assays were performed using confluent monolayers of BSC40 cells. The bar plot shows the virucidal activity after a 2-minute exposure, showing 8-log reduction, alongside images of crystal violet-stained plaque assays (1% crystal violet, 70% ethanol) after 30 minutes. b Analytical sensitivity of LAMP assays: range of detected concentrations of synthetic DNA (log10 of copies per reaction) and corresponding TTP values in minutes. c Analytical specificity of LAMP assays: Using extracted nucleic acids from various commercially available viral particles (MXPV, HSV-1/HSV-2, and VZV), and a control sample consisting of synthetic DNA at 5 × 10³ copies per reaction. The bar plot displays mean TTP values and data points (in minutes) with error bars representing the standard deviation (SD). d qPCR Ct values distribution: A histogram illustrating the distribution of qPCR Ct values obtained from OPXV and MPXV-positive clinical samples (purple dots for OPXV and yellow dashed lines for MPXV). Confusion matrices of the diagnostic performance are included below. e Sample-to-result demonstration: Images showing the results for vaccinia (VACV), cowpox (CPXV), MPXV, and combined HSV-1/HSV-2/VZV viral particles, with spiking concentrations indicated below each set of reactions. VACV and CPXV viral particles, both spiked at 5 × 105 PFU/mL, demonstrate the specificity of the OPXV assay, showing no cross-reactivity with other target assays. Similarly, spiking MPXV (2.5 × 10³ copies/mL) and combined HSV-1/HSV-2/VZV viral particles (2.5 × 10³ copies/mL for VZV and HSV-1, 3.5 × 10³ copies/mL for HSV-2) showed no cross-reactivity. Created in BioRender. Cavuto, M. (2025) https://BioRender.com/d45n457.
